Key Details
Price
$122.36Annual ROE
12.16%Beta
0.43Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 06, 2024Recent annual earnings:
Feb 28, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
The average price target suggests that Jazz (JAZZ) could increase by 44.4%. Although studies indicate that this measure is not very reliable, an increase in earnings estimate revisions might indicate that the stock could rise soon.
After receiving approval from the FDA, Jazz's Ziihera is now the first bispecific antibody that targets two HER2 proteins and is a chemotherapy-free option for treating biliary tract cancer.
On Wednesday, Jazz Pharmaceuticals announced that the U.S. Food and Drug Administration has approved their medication, zanidatamab-hrii, for treating a specific kind of biliary tract cancer.
At Zacks, we concentrate on the reliable Zacks Rank system, which highlights earnings estimates and changes in those estimates to identify excellent stocks. However, we also keep an eye on the most recent trends in value, growth, and momentum to support our top selections.
Investors should closely monitor Jazz (JAZZ) stock due to recent changes in the options market.
Jazz (JAZZ) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
Analysts' average price targets for Jazz (JAZZ) suggest that the stock could increase by 37.7%. Although this popular measure hasn't always been very reliable, the strong consensus among analysts in increasing their earnings forecasts suggests that the stock may rise.
Investors looking at Medical - Drugs stocks probably know about Jazz Pharmaceuticals (JAZZ) and Catalent (CTLT). However, which of these two stocks is more appealing for value investors?
Jazz Pharmaceuticals (JAZZ) reported quarterly earnings of $6.61 per share, which is higher than the Zacks Consensus Estimate of $5.47 per share. This is an increase compared to earnings of $4.84 per share from the same period last year.
Jazz Pharmaceuticals plc announced the first presentation of key efficacy and safety results from the Phase 4 DUET trial, which focuses on adults with narcolepsy or idiopathic hypersomnia. This announcement was made for U.S. media and investors only. The data was showcased at the 37th annual Psych Congress in Boston, where eight abstracts from their sleep portfolio were presented.
FAQ
- What is the primary business of Jazz Pharmaceuticals?
- What is the ticker symbol for Jazz Pharmaceuticals?
- Does Jazz Pharmaceuticals pay dividends?
- What sector is Jazz Pharmaceuticals in?
- What industry is Jazz Pharmaceuticals in?
- What country is Jazz Pharmaceuticals based in?
- When did Jazz Pharmaceuticals go public?
- Is Jazz Pharmaceuticals in the S&P 500?
- Is Jazz Pharmaceuticals in the NASDAQ 100?
- Is Jazz Pharmaceuticals in the Dow Jones?
- When was Jazz Pharmaceuticals's last earnings report?
- When does Jazz Pharmaceuticals report earnings?
- Should I buy Jazz Pharmaceuticals stock now?